• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 TGN1412 临床试验悲剧中,单核细胞是否是引发细胞因子风暴的罪魁祸首?

Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?

机构信息

University Department of Pathology, Western Infirmary, Glasgow, UK.

出版信息

Clin Exp Immunol. 2010 Dec;162(3):516-27. doi: 10.1111/j.1365-2249.2010.04264.x. Epub 2010 Oct 21.

DOI:10.1111/j.1365-2249.2010.04264.x
PMID:20964641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3026555/
Abstract

The precise biological mechanisms that caused the TGN1412 clinical trial tragedy (also known as 'The Elephant Man Clinical Trial') in March 2006 remain a mystery to this day. It is assumed widely that the drug used in this trial (TGN1412) bound to CD28 on T lymphocytes and following activation of these cells, a massive 'cytokine storm' ensued, leading ultimately to multi-organ failure in all recipients. The rapidity of this in vivo response (within 2 h), however, does not fit well with a classical T lymphocyte response, suggesting that other 'faster-acting' cell types may have been involved. In this study we have activated purified human peripheral blood leucocyte populations using various clones of mouse monoclonal anti-CD28 presented to cells in the form of a multimeric array. Cytokines were measured in cell-free supernatants at 2 h, and specific mRNA for tumour necrosis factor (TNF)-α, thought to be the initiator of the cytokine storm, was also measured in cell lysates by reverse transcription-polymerase chain reaction (RT-PCR). Monocytes were the only cell type found to show significant (P < 0·05) up-regulation of TNF-α at 2 h. Eleven other monocyte cytokines were also up-regulated by anti-CD28 within this time-frame. It therefore seems likely that monocytes and not T cells, as widely believed, were probably responsible, at least in part, for initiating the cytokine storm. Furthermore, we propose that a multimeric antibody array may have formed in vivo on the vascular endothelium via an interaction between TGN1412 and CD64 (FcγRI), and we provide some evidence in support of this hypothesis.

摘要

导致 2006 年 3 月 TGN1412 临床试验悲剧(也称为“象人临床试验”)的确切生物学机制至今仍是个谜。人们普遍认为,该试验中使用的药物(TGN1412)与 T 淋巴细胞上的 CD28 结合,随后这些细胞被激活,引发大规模的“细胞因子风暴”,最终导致所有接受者的多器官衰竭。然而,这种体内反应的速度(在 2 小时内)与经典的 T 淋巴细胞反应不太吻合,这表明可能涉及其他“作用更快”的细胞类型。在这项研究中,我们使用各种形式的多聚体阵列将小鼠单克隆抗 CD28 克隆递呈给细胞,以激活纯化的人外周血白细胞群体。在 2 小时时测量细胞因子在无细胞上清液中的浓度,并通过逆转录聚合酶链反应 (RT-PCR) 在细胞裂解物中测量肿瘤坏死因子 (TNF)-α 的特异性 mRNA,认为它是细胞因子风暴的启动子。只有单核细胞显示出在 2 小时时 TNF-α 的显著(P < 0·05)上调。在这段时间内,其他 11 种单核细胞细胞因子也被抗 CD28 上调。因此,单核细胞而不是 T 细胞(如广泛认为的那样)可能至少部分负责引发细胞因子风暴。此外,我们提出多聚体抗体阵列可能通过 TGN1412 与 CD64(FcγRI)之间的相互作用在血管内皮细胞中形成体内,并且我们提供了一些支持该假设的证据。

相似文献

1
Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?在 TGN1412 临床试验悲剧中,单核细胞是否是引发细胞因子风暴的罪魁祸首?
Clin Exp Immunol. 2010 Dec;162(3):516-27. doi: 10.1111/j.1365-2249.2010.04264.x. Epub 2010 Oct 21.
2
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.单克隆抗体 TGN1412 试验失败归因于 CD4+效应记忆 T 细胞上 CD28 表达的种属差异。
Br J Pharmacol. 2010 Oct;161(3):512-26. doi: 10.1111/j.1476-5381.2010.00922.x.
3
Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.人 Fcγ 受体竞争与 TGN1412 的结合,这决定了抗体的效应功能。
Eur J Immunol. 2019 Jul;49(7):1117-1126. doi: 10.1002/eji.201847924. Epub 2019 Apr 29.
4
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.高细胞密度预培养 PBMC 可提高 T 细胞反应的灵敏度,揭示 CD28 超激动剂 TGN1412 引起的细胞因子释放。
Blood. 2011 Dec 22;118(26):6772-82. doi: 10.1182/blood-2010-12-319780. Epub 2011 Sep 19.
5
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.改进的体外方法可预测治疗性单克隆抗体(包括 TGN1412)在人体内的毒性。
J Immunol Methods. 2010 Jan 31;352(1-2):1-12. doi: 10.1016/j.jim.2009.10.013. Epub 2009 Nov 4.
6
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.重组H22(单链抗体片段)可阻断CD64并防止抗TNF单克隆抗体的捕获。这是一种增强抗TNF治疗的潜在策略。
MAbs. 2014;6(5):1283-9. doi: 10.4161/mabs.32182.
7
Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.无法上调细胞表面程序性死亡受体1(PD-1)与TGN1412样CD28超激动剂对T细胞的刺激失调有关。
MAbs. 2014;6(5):1290-9. doi: 10.4161/mabs.29758. Epub 2014 Oct 30.
8
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.上调单核细胞上的 FcγRIIb 对于促进 TGN1412 的超强激动剂活性是必要的。
Blood. 2015 Jan 1;125(1):102-10. doi: 10.1182/blood-2014-08-593061. Epub 2014 Nov 13.
9
Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.使用体外检测和两种免疫人源化小鼠模型评估 TGN1412 类似物。
Toxicol Appl Pharmacol. 2019 Jun 1;372:57-69. doi: 10.1016/j.taap.2019.03.020. Epub 2019 Mar 23.
10
The calm after the cytokine storm: lessons from the TGN1412 trial.细胞因子风暴后的平静:来自TGN1412试验的教训
J Clin Invest. 2008 Apr;118(4):1344-7. doi: 10.1172/JCI35382.

引用本文的文献

1
"Cytokine storm", not only in COVID-19 patients. Mini-review.“细胞因子风暴”,不仅在 COVID-19 患者中。小型综述。
Immunol Lett. 2020 Dec;228:38-44. doi: 10.1016/j.imlet.2020.09.007. Epub 2020 Sep 29.
2
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?在不影响治疗效果的前提下提高基于抗体的免疫调节癌症治疗的安全性:我们能否两全其美?
Expert Opin Biol Ther. 2016;16(5):655-74. doi: 10.1517/14712598.2016.1152256. Epub 2016 Feb 25.
3
Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.无法上调细胞表面程序性死亡受体1(PD-1)与TGN1412样CD28超激动剂对T细胞的刺激失调有关。
MAbs. 2014;6(5):1290-9. doi: 10.4161/mabs.29758. Epub 2014 Oct 30.
4
Dynamics of a cytokine storm.细胞因子风暴的动力学。
PLoS One. 2012;7(10):e45027. doi: 10.1371/journal.pone.0045027. Epub 2012 Oct 1.
5
After TGN1412: recent developments in cytokine release assays.TGN1412 事件后:细胞因子释放检测的最新进展。
J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. doi: 10.3109/1547691X.2012.711783. Epub 2012 Sep 11.
6
CD28 ligation increases macrophage suppression of T-cell proliferation.CD28 交联增加了巨噬细胞对 T 细胞增殖的抑制作用。
Cell Mol Immunol. 2012 Jul;9(4):341-9. doi: 10.1038/cmi.2012.13. Epub 2012 Apr 23.
7
Granzyme B- and Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4+ T cells.丝氨酸蛋白酶家族成员颗粒酶 B 和 Fas 配体介导的细胞毒性功能由有丝分裂原 CD28 刺激人记忆性 CD4+T 细胞引起。
J Leukoc Biol. 2012 May;91(5):759-71. doi: 10.1189/jlb.0511264. Epub 2012 Mar 13.

本文引用的文献

1
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.抗人CD28超激动剂抗体的信号特征和功能特性。
PLoS One. 2008 Mar 5;3(3):e1708. doi: 10.1371/journal.pone.0001708.
2
Regulation of interferon-gamma during innate and adaptive immune responses.先天性和适应性免疫反应期间干扰素-γ的调节
Adv Immunol. 2007;96:41-101. doi: 10.1016/S0065-2776(07)96002-2.
3
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.单克隆抗体TGN1412一期试验中的“细胞因子风暴”:更好地理解原因以改进免疫疗法的临床前测试
J Immunol. 2007 Sep 1;179(5):3325-31. doi: 10.4049/jimmunol.179.5.3325.
4
Cytokine storm and an anti-CD28 monoclonal antibody.细胞因子风暴与一种抗CD28单克隆抗体。
N Engl J Med. 2006 Dec 14;355(24):2592-3; author reply 2593-4. doi: 10.1056/NEJMc062750.
5
Major histocompatibility complex class II (DR) antigen and costimulatory molecules on in vitro and in vivo activated human polymorphonuclear neutrophils.体外和体内活化的人多形核中性粒细胞上的主要组织相容性复合体II类(DR)抗原和共刺激分子
Immunology. 2006 Dec;119(4):562-71. doi: 10.1111/j.1365-2567.2006.02471.x. Epub 2006 Oct 11.
6
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.抗CD28单克隆抗体TGN1412 1期试验中的细胞因子风暴
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
7
CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.CD28超激动剂通过优先激活CD4+CD25+调节性T细胞来抑制自身免疫。
Autoimmun Rev. 2006 Jan;5(1):40-5. doi: 10.1016/j.autrev.2005.06.001. Epub 2005 Jul 7.
8
Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.超激动性抗CD28抗体:用于自身免疫性疾病治疗的调节性T细胞强效激活剂。
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv91-5. doi: 10.1136/ard.2005.042564.
9
CD28 superagonists: mode of action and therapeutic potential.CD28超激动剂:作用模式与治疗潜力
Immunol Lett. 2005 Aug 15;100(1):21-8. doi: 10.1016/j.imlet.2005.06.012.
10
Mechanisms of eosinophil cytokine release.嗜酸性粒细胞细胞因子释放的机制。
Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1(Suppl 1):73-81. doi: 10.1590/s0074-02762005000900013. Epub 2005 Jun 14.